No­var­tis, BeiGene's PD-(L)1 play takes home an­oth­er win in late-stage da­ta, adding some heft to its mar­ket po­ten­tial

Con­tin­u­ing its quest to shake up the PD-1 mar­ket, BeiGene re­vealed more da­ta Fri­day for its check­point in­hibitor tislelizum­ab, this time in re­cur­rent or metasta­t­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER